Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Heparin × Plasma cell × Clear all

Phase

Status

Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Other hematologic neoplasm 1 Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1 Multiple Myeloma 1

Interventions

Dexamethasone 101 Bortezomib 56 Cyclophosphamide 48 Lenalidomide 43 Calcium Dobesilate 42 Melphalan 34 pomalidomide 32 fludarabine 26 Filgrastim 23 carfilzomib 20 fludarabine phosphate 19 daratumumab 18 Whole-Body Irradiation 16 Mycophenolic Acid 15 Granulocyte Colony-Stimulating Factor 15 Antilymphocyte Serum 14 dexamethasone acetate 13 Thalidomide 12 Tacrolimus 12 Radiotherapy 12 Peripheral Blood Stem Cell Transplantation 12 Cyclosporine 12 Busulfan 11 dexamethasone 21-phosphate 9 auricularum 9 Stem Cell Transplantation 9 Rituximab 9 pembrolizumab 8 belantamab mafodotin 8 Etoposide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated

63 enrolled 14 charts

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡